137 related articles for article (PubMed ID: 34243925)
1. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy.
Kampalath R; Tran-Harding K; Do RKG; Mendiratta-Lala M; Yaghmai V
Magn Reson Imaging Clin N Am; 2021 Aug; 29(3):389-403. PubMed ID: 34243925
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
3. Optimal imaging criteria and modality to determine Milan criteria for the prediction of post-transplant HCC recurrence after locoregional treatment.
Seo N; Joo DJ; Park MS; Kim SS; Shin HJ; Chung YE; Choi JY; Kim MS; Kim MJ
Eur Radiol; 2023 Jan; 33(1):501-511. PubMed ID: 35821427
[TBL] [Abstract][Full Text] [Related]
4. Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI.
Patel R; Aslam A; Parikh ND; Mervak B; Mubarak E; Higgins L; Lala K; Conner JF; Khaykin V; Bashir M; Do RKG; Burke LMB; Smith EN; Kim CY; Shampain KL; Owen D; Mendiratta-Lala M
J Magn Reson Imaging; 2023 Jun; 57(6):1641-1654. PubMed ID: 36872608
[TBL] [Abstract][Full Text] [Related]
5. Artificial intelligence in assessment of hepatocellular carcinoma treatment response.
Spieler B; Sabottke C; Moawad AW; Gabr AM; Bashir MR; Do RKG; Yaghmai V; Rozenberg R; Gerena M; Yacoub J; Elsayes KM
Abdom Radiol (NY); 2021 Aug; 46(8):3660-3671. PubMed ID: 33786653
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
[No Abstract] [Full Text] [Related]
8. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.
Kielar A; Fowler KJ; Lewis S; Yaghmai V; Miller FH; Yarmohammadi H; Kim C; Chernyak V; Yokoo T; Meyer J; Newton I; Do RK
Abdom Radiol (NY); 2018 Jan; 43(1):218-230. PubMed ID: 28780679
[TBL] [Abstract][Full Text] [Related]
9. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
11. Evaluation and Prediction of Treatment Response for Hepatocellular Carcinoma.
Tsujita Y; Sofue K; Ueshima E; Ueno Y; Hori M; Tsurusaki M; Murakami T
Magn Reson Med Sci; 2023 Apr; 22(2):209-220. PubMed ID: 36792205
[TBL] [Abstract][Full Text] [Related]
12. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.
Aslam A; Kamath A; Spieler B; Maschiocchi M; Sabottke CF; Chernyak V; Lewis SC
Abdom Radiol (NY); 2021 Aug; 46(8):3565-3578. PubMed ID: 33856509
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization.
Kierans AS; Najjar M; Dutruel SP; Gavlin A; Chen C; Lee MJ; Askin G; Halazun KJ
Clin Imaging; 2021 Dec; 80():117-122. PubMed ID: 34303189
[TBL] [Abstract][Full Text] [Related]
14. LI-RADS treatment response assessment of combination locoregional therapy for HCC.
Gerena M; Molvar C; Masciocchi M; Nandwana S; Sabottke C; Spieler B; Sharma R; Tsai L; Kielar A
Abdom Radiol (NY); 2021 Aug; 46(8):3634-3647. PubMed ID: 34120207
[TBL] [Abstract][Full Text] [Related]
15. Imaging After Locoregional Therapy for Hepatocellular Carcinoma with Emphasis on LIRADS Treatment Response Assessment Criteria.
Bajaj G; Sundaram K; Jambhekar K; Ram R
Semin Ultrasound CT MR; 2021 Aug; 42(4):318-331. PubMed ID: 34130846
[TBL] [Abstract][Full Text] [Related]
16. LI-RADS treatment response lexicon: review, refresh and resolve with emerging data.
Ram R; Kampalath R; Shenoy-Bhangle AS; Arora S; Kielar AZ; Mendiratta-Lala M
Abdom Radiol (NY); 2021 Aug; 46(8):3549-3557. PubMed ID: 34106301
[TBL] [Abstract][Full Text] [Related]
17. Imaging diagnosis of hepatocellular carcinoma: LI-RADS.
Cunha GM; Sirlin CB; Fowler KJ
Chin Clin Oncol; 2021 Feb; 10(1):3. PubMed ID: 32527115
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions.
Aslam A; Do RKG; Kambadakone A; Spieler B; Miller FH; Gabr AM; Charalel RA; Kim CY; Madoff DC; Mendiratta-Lala M
World J Hepatol; 2020 Oct; 12(10):738-753. PubMed ID: 33200013
[TBL] [Abstract][Full Text] [Related]
19. LI-RADS: Past, Present, and Future, From the
Marks RM; Masch WR; Chernyak V
AJR Am J Roentgenol; 2021 Feb; 216(2):295-304. PubMed ID: 33052720
[TBL] [Abstract][Full Text] [Related]
20. Imaging After Locoregional Therapy for Hepatocellular Carcinoma With Emphasis on LIRADS Treatment Response Assessment Criteria.
Bajaj G; Sundaram K; Jambhekar K; Ram R
Semin Ultrasound CT MR; 2021 Aug; 42(4):390-404. PubMed ID: 34130851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]